This open-label 24-week extension study evaluated the safety, clinical and biological activity of C2L 30mg in acromegalic patients. Mean efficacy on IGF-1 was identical, throughout Study 302, to what it was after 84 days (12 weeks) of treatment in the first part of Study 301 with either C2L or SLAR. This suggests that switching from SLAR every four weeks to C2L every six weeks does not induce a decrease in IGF-1 response, even after 36 additional weeks follow-up.

Efficacy on GH was also maintained throughout Study 302, again supporting that switching from SLAR every four weeks to C2L every six weeks at the same dose yields the same efficacy on GH control in acromegalics over an extended period of time. The number of patients with normalized IGF-1 or GH levels was identical or slightly higher (though not significantly) after treatment with C2L as compared to SLAR.

Overall, the top-line analysis of the results supports the ability of C2L 30mg given every six weeks to replace SLAR given every four weeks at the same dose, with mean efficacy and safety maintained over an additional six months treatment. The company expects regulatory filings to be initiated before the end of 2008.

Philippe Calais, president and CEO of Ambrilia, said: "These new data further validate C2L's potential to be a safe, effective and cost-effective therapy, well positioned to capture a sizeable portion of the $1 billion-plus SLAR market. Again, we are progressing well toward our year-end divestment goal for C2L which could alleviate the company's financial overhang by bringing non-dilutive funding."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Protease inhibitors are a key component to the current HIV/AIDS standard of care, the Highly Active Anti-Retroviral Treatment (HAART) consisting of a cocktail of HIV medicines.

About the Ambrilia and Merck Partnership

In October 2006, Ambrilia entered into an exclusive licensing agreement granting Merck & Co. - through an affiliate - the worldwide rights to its HIV protease inhibitor program, including lead compound PPL-100. In return, Ambrilia received an upfront payment of $US 17 million and is eligible for potential cash payments totaling $US212 million upon successful completion of development, clinical, regulatory and sales milestones, and royalties on all future product sales. The agreement also provides for additional milestone-based cash payments and royalties on the future development and commercialization of each back-up compound and/or related compounds developed by Merck and which fall within the scope of the Ambrilia HIV protease inhibitor program.

AMBRILIA'S FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. There is a risk that expectations and forward looking statements will not prove to be accurate. Readers are cautioned not to place undue reliance on these forward-looking statements as they involve risks and uncertainties, which could make actual results differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company's filings. We refer you to the Risk Factors section of the Company's annual information form which contains a more exhaustive analysis of the risks and uncertainties that are generally connected to the business of the Company. Such statements are also based on various assumptions, including the successful and timely completion of clinical studies on Ambrilia's products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia's views to change, Ambrilia specifically disclaims any obligation to update these forward looking statements, unless obligated to do so by applicable securities laws.

ABOUT AMBRILIA BIOPHARMA

Ambrilia Biopharma Inc. (TSX: AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. The Company's strategy aims to capitalize on its broad portfolio and original expertise in virology. Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery technology for cancer, an HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.) as well as HIV integrase and entry inhibitors, HCV entry and polymerase inhibitors and Anti-Influenza A compounds. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France.

Contacts:
Ambrilia Biopharma inc.
Julie M. Thibodeau, B.Sc., MBA
Director, Communications
514-751-2003 ext 235
jthibodeau@ambrilia.com / ir@ambrilia.com
www.ambrilia.com

SOURCE: Ambrilia Biopharma inc.

mailto:jthibodeau@ambrilia.com
mailto:ir@ambrilia.com
http://www.ambrilia.com

Ambrilia Biopharma Inc. (TSX: AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. The Company's strategy aims to capitalize on its broad portfolio and original expertise in virology. Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery technology for cancer, an HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.) as well as HIV integrase and entry inhibitors, Hepatitis C inhibitors and anti-Influenza A compounds. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France.

For more information, please visit the Company's web site: www.ambrilia.com

Contacts:
Ambrilia Biopharma Inc.
Julie M. Thibodeau, B.Sc., MBA
Director, Communications
514-751-2003 ext 235
jthibodeau@ambrilia.com or ir@ambrilia.com
www.ambrilia.com

SOURCE: Ambrilia Biopharma Inc.

mailto:jthibodeau@ambrilia.com
mailto:ir@ambrilia.com
http://www.ambrilia.com

ABOUT AMBRILIA BIOPHARMA

Ambrilia Biopharma Inc. (TSX: AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. The Company's strategy aims to capitalize on its broad portfolio and original expertise in virology. Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery technology for cancer, an HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.) as well as HIV integrase and entry inhibitors, Hepatitis C inhibitors and anti-Influenza A compounds. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France.

For more information, please visit the Company's web site: www.ambrilia.com Contacts: Ambrilia Biopharma Inc. Julie M. Thibodeau, B.Sc., MBA Director, Communications 514-751-2003, ext. 235 jthibodeau@ambrilia.com or ir@ambrilia.com www.ambrilia.com

SOURCE: Ambrilia Biopharma Inc.